Off Topic Compare the cheese to no 10 thread
- Thread starter Red Hadron Collider
- Start date
-
Please bear with us on the new site integration and fixing any known bugs over the coming days. If you can not log in please try resetting your password and check your spam box. If you have tried these steps and are still struggling email [email protected] with your username/registered email address
-
****ing hell! The plastic drain pipes were easier to carry.
Metal scsffolding was more accurate
We used to play war with Gat pistols and pigeon darts, how no one lost an eye I don't know. The other favourite was firing Acorns from catapults, someone did get a serious eye injury from that when some idiot fired one into a crowded corridor in school one day, not me I hasten to add, but the ensuing search of lockers and desks by the teachers produced an abundance of catapults, Gats, stanley knives, flick knives and even an 8ft leather whip!
I remember when we went paint balling once and my mate took his mask off at the end but before the game was officially dead and got hit in the forehead right between the eyes ****ing piss funny at the time like the fireworks stuff but could've been potentially life changing!
****ing piss funny at the time like the fireworks stuff but could've been potentially life changing!
Had a bunch of lads when i was young where we'd go out in the fields with air rifles, pistols, bb guns, catapults, rocks, knives and just ****in go at each other. One lad got capped in the leg once and it went infected and he had to stay in hospital
In school a favoured weapon was always a big ball of blu tac with drawing pins embedded in it, spike side out of course, like one of those spiky sea mines which you'd just launch at someone unsuspecting and see if it would hang off the skin
This is the presentation for one of my candidates in his forthcoming interview 
Please prepare a short (20 min) presentation on a topic of your choice, and allocate an additional 20 minutes at the end of your presentation to address the following task:
The RNA methyltransferase METTL16 has been recently reported to bind to MALAT1 lncRNA (Brown et al., PNAS 2016) and to the 3’UTR of MAT2A mRNA (Pendleton et al., Cell 2017). In addition, METTL16 was shown to mediate m6A modification of U6 snRNA and MAT2A mRNA (Pendleton et al., Cell 2017; Warda et al., EMBO Rep 2017). A CRISPR KO screen of RNA modifying enzymes performed at Storm identified METTL16 as an essential gene specifically in AML cells (but not in CML cells, normal hematopoietic stem cells and several cancer cell lines from different tissue origins). Please present your strategy for strengthening target validation and disease positioning of METTL16, and outline how you would develop a therapeutically relevant in vitro and in vivo screening cascade for a potential METTL16 drug discovery programme, including assessment of target engagement and PK/PD relationship. Please also outline your initial thoughts on developing a potential patient stratification route and Target Product Profile.
Please prepare a short (20 min) presentation on a topic of your choice, and allocate an additional 20 minutes at the end of your presentation to address the following task:
The RNA methyltransferase METTL16 has been recently reported to bind to MALAT1 lncRNA (Brown et al., PNAS 2016) and to the 3’UTR of MAT2A mRNA (Pendleton et al., Cell 2017). In addition, METTL16 was shown to mediate m6A modification of U6 snRNA and MAT2A mRNA (Pendleton et al., Cell 2017; Warda et al., EMBO Rep 2017). A CRISPR KO screen of RNA modifying enzymes performed at Storm identified METTL16 as an essential gene specifically in AML cells (but not in CML cells, normal hematopoietic stem cells and several cancer cell lines from different tissue origins). Please present your strategy for strengthening target validation and disease positioning of METTL16, and outline how you would develop a therapeutically relevant in vitro and in vivo screening cascade for a potential METTL16 drug discovery programme, including assessment of target engagement and PK/PD relationship. Please also outline your initial thoughts on developing a potential patient stratification route and Target Product Profile.
Doddle.This is the presentation for one of my candidates in his forthcoming interview
Please prepare a short (20 min) presentation on a topic of your choice, and allocate an additional 20 minutes at the end of your presentation to address the following task:
The RNA methyltransferase METTL16 has been recently reported to bind to MALAT1 lncRNA (Brown et al., PNAS 2016) and to the 3’UTR of MAT2A mRNA (Pendleton et al., Cell 2017). In addition, METTL16 was shown to mediate m6A modification of U6 snRNA and MAT2A mRNA (Pendleton et al., Cell 2017; Warda et al., EMBO Rep 2017). A CRISPR KO screen of RNA modifying enzymes performed at Storm identified METTL16 as an essential gene specifically in AML cells (but not in CML cells, normal hematopoietic stem cells and several cancer cell lines from different tissue origins). Please present your strategy for strengthening target validation and disease positioning of METTL16, and outline how you would develop a therapeutically relevant in vitro and in vivo screening cascade for a potential METTL16 drug discovery programme, including assessment of target engagement and PK/PD relationship. Please also outline your initial thoughts on developing a potential patient stratification route and Target Product Profile.
Garlic Klopp said:
Marbles were much better
Yeah, but you lost your marbles.
yup.
5min into yourself.
10min waffle showing structure of thinking
5min wrap up/questions.
it e an gives you the topics headings in detail.
I could throw that together off Google.
what?
seriously.... its not rocket science
I should know i did a presentation style interview recently. aced it too
Must be a proper ****ing nerdThis is the presentation for one of my candidates in his forthcoming interview
Please prepare a short (20 min) presentation on a topic of your choice, and allocate an additional 20 minutes at the end of your presentation to address the following task:
The RNA methyltransferase METTL16 has been recently reported to bind to MALAT1 lncRNA (Brown et al., PNAS 2016) and to the 3’UTR of MAT2A mRNA (Pendleton et al., Cell 2017). In addition, METTL16 was shown to mediate m6A modification of U6 snRNA and MAT2A mRNA (Pendleton et al., Cell 2017; Warda et al., EMBO Rep 2017). A CRISPR KO screen of RNA modifying enzymes performed at Storm identified METTL16 as an essential gene specifically in AML cells (but not in CML cells, normal hematopoietic stem cells and several cancer cell lines from different tissue origins). Please present your strategy for strengthening target validation and disease positioning of METTL16, and outline how you would develop a therapeutically relevant in vitro and in vivo screening cascade for a potential METTL16 drug discovery programme, including assessment of target engagement and PK/PD relationship. Please also outline your initial thoughts on developing a potential patient stratification route and Target Product Profile.
This is the presentation for one of my candidates in his forthcoming interview
Please prepare a short (20 min) presentation on a topic of your choice, and allocate an additional 20 minutes at the end of your presentation to address the following task:
The RNA methyltransferase METTL16 has been recently reported to bind to MALAT1 lncRNA (Brown et al., PNAS 2016) and to the 3’UTR of MAT2A mRNA (Pendleton et al., Cell 2017). In addition, METTL16 was shown to mediate m6A modification of U6 snRNA and MAT2A mRNA (Pendleton et al., Cell 2017; Warda et al., EMBO Rep 2017). A CRISPR KO screen of RNA modifying enzymes performed at Storm identified METTL16 as an essential gene specifically in AML cells (but not in CML cells, normal hematopoietic stem cells and several cancer cell lines from different tissue origins). Please present your strategy for strengthening target validation and disease positioning of METTL16, and outline how you would develop a therapeutically relevant in vitro and in vivo screening cascade for a potential METTL16 drug discovery programme, including assessment of target engagement and PK/PD relationship. Please also outline your initial thoughts on developing a potential patient stratification route and Target Product Profile.
The answer is 42
The candidate
The candidate with a PhD in cancer biology and 12 years post-doc experience. Yeah, total ****
I didn't say ****, I said nerd.The candidate with a PhD in cancer biology and 12 years post-doc experience. Yeah, total ****
Seems I was right